Recent Advances Revolutionize Treatment of Metastatic Prostate Cancer

Ravi A Madan; Philip M Arlen


Future Oncol. 2013;9(8):1133-1144. 

In This Article

Future Perspective

With the abundance of new therapies available in the treatment of prostate cancer come practical dilemmas regarding cost. It is important to note that the high price of these new therapies may not be sustainable given the growing economic concerns of healthcare and there is no clear mechanism by which these issues can be addressed in clinical development. This is a problem not just limited to oncology, and it is probably an issue that cannot be ignored as these and other agents emerge in the treatment of prostate cancer.

Nonetheless, the rapid emergence of therapies in the last few years has led to questions of how they can best be deployed in clinical practice. Current and future trials will also investigate how best to sequence these new hormonal agents, immunotherapies, radiopharmaceuticals and targeted molecular therapies, and whether they are more effective when used in combination or sequentially. The responsibilities that come with multiple new therapies are a welcome dilemma for clinicians who just a few years ago had limited options for their patients with mCRPC. In spite of these novel agents, it should be clear that the judicious use of chemotherapy in more advanced and symptomatic mCRPC will still have a very important palliative and therapeutic role as we move into this new age of therapy. In recent years, great strides have been made in treatments for mCRPC. Applying this knowledge in the non-metastatic and adjuvant settings to enhance the cure rate for prostate cancer should be the ultimate goal.